CJC-1295 (No DAC) + Ipamorelin Blend

Description

CJC-1295 (No DAC) + Ipamorelin 5/5 Blend (Synergistic Growth Hormone Secretagogue Combination)

Concentration: 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial
Form: Lyophilized Powder
Storage: Store at −20 °C. Protect from light and moisture.

Molecular Formula (CJC-1295 No DAC): C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3,364.70 g/mol
Molecular Formula (Ipamorelin): C₃₈H₄₉N₉O₅
Molecular Weight: 711.86 g/mol
Purity: ≥98 % (HPLC)

Description

The CJC-1295 (No DAC) + Ipamorelin 5/5 Blend is a dual growth hormone secretagogue formulation designed to model both hypothalamic (GHRH-mediated) and pituitary (ghrelin receptor-mediated) activation of the somatotropic axis.
This combination induces synergistic pulsatile growth hormone (GH) release, closely mimicking physiological secretion patterns observed in healthy individuals.

• CJC-1295 (No DAC) acts as a GHRH receptor agonist, stimulating GH synthesis and release through cAMP-dependent signaling while maintaining normal feedback sensitivity.

• Ipamorelin, a selective GHSR-1a agonist, triggers GH release via phospholipase C-driven calcium mobilization with minimal impact on cortisol or prolactin levels.

Together, these peptides produce a balanced, high-amplitude GH pulse and prolonged elevation of IGF-1, making the blend a valuable research model for studying pituitary regulation, metabolic function, and recovery physiology.

Intended Use

This product is intended for laboratory research use only.
It is not for human consumption, diagnostic, or therapeutic applications.
All handling should be performed by qualified professionals in a controlled research environment.

Key Research Applications

• Investigation of synergistic GH/IGF-1 release mechanisms via dual receptor activation

• Studies on endocrine feedback control and somatotropic rhythm modulation

• Research on metabolic regulation, muscle recovery, and cellular repair

• Analysis of short-acting GH secretagogues in combined administration protocols